IL199689A0 - Compounds and method for treatment of cancer - Google Patents

Compounds and method for treatment of cancer

Info

Publication number
IL199689A0
IL199689A0 IL199689A IL19968909A IL199689A0 IL 199689 A0 IL199689 A0 IL 199689A0 IL 199689 A IL199689 A IL 199689A IL 19968909 A IL19968909 A IL 19968909A IL 199689 A0 IL199689 A0 IL 199689A0
Authority
IL
Israel
Prior art keywords
cancer
compounds
treatment
Prior art date
Application number
IL199689A
Other languages
English (en)
Original Assignee
Critical Outcome Technologies
Danter Wayne
Brown Martyn
Lepifre Franck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Outcome Technologies, Danter Wayne, Brown Martyn, Lepifre Franck filed Critical Critical Outcome Technologies
Publication of IL199689A0 publication Critical patent/IL199689A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL199689A 2007-01-11 2009-07-05 Compounds and method for treatment of cancer IL199689A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88448907P 2007-01-11 2007-01-11
US88450407P 2007-01-11 2007-01-11
PCT/CA2008/000045 WO2008083491A1 (en) 2007-01-11 2008-01-11 Compounds and method for treatment of cancer

Publications (1)

Publication Number Publication Date
IL199689A0 true IL199689A0 (en) 2010-04-15

Family

ID=39608296

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199689A IL199689A0 (en) 2007-01-11 2009-07-05 Compounds and method for treatment of cancer

Country Status (6)

Country Link
US (4) US8034815B2 (enExample)
EP (1) EP2121681B1 (enExample)
JP (1) JP5571387B2 (enExample)
CA (1) CA2673683C (enExample)
IL (1) IL199689A0 (enExample)
WO (1) WO2008083491A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138191B2 (en) * 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20140271812A1 (en) * 2013-03-14 2014-09-18 Panacea Pharmaceuticals Treatment for chemotherapy-induced cognitive impairment
WO2017024315A1 (en) * 2015-08-06 2017-02-09 Nant Holdings Ip, Llc Heterocyclic thiosemicarbazone derivatives and their therapeutical applications
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239539A (en) 1960-12-02 1966-03-08 Exxon Research Engineering Co Gem dimethylol alicyclic esters
GB1026401A (en) 1961-02-23 1966-04-20 Wellcome Found Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them
US3250791A (en) 1961-12-29 1966-05-10 Du Pont Tetracyanoethylene oxide and process for preparing same
GB1231783A (en) 1967-05-16 1971-05-12 May & Baker Ltd Benzene derivatives
DE1767924A1 (de) 1968-07-02 1971-10-07 Bayer Ag 1-Phenyl-4,4-dialkyl-thiosemicarbazide
JPS5695161A (en) * 1979-12-28 1981-08-01 Otsuka Pharmaceut Factory Inc 2-admantanon derivative
EP0096989A3 (en) 1982-05-26 1984-11-14 Toray Industries, Inc. Electrophotographic photosensitive material
US4537844A (en) 1982-10-08 1985-08-27 Ricoh Co. Ltd. Electrophotographic element containing disazo compound
CA1217491A (en) 1982-10-11 1987-02-03 Erhardt Winkelmann 3-aryl-7-chloro-3,4-dihydroacridine-1,9(2h,10h)-dione 1-oximes and 1-hydrazone derivatives, their salts, a process for their preparation, agents containing them and their use
DE3237649A1 (de) 1982-10-11 1984-04-12 Hoechst Ag, 6230 Frankfurt 3-aryl-7-chlor-10-hydroxy-3,4-dihydro-acridin-1,9-(2h, 10h)-dion-1-oxime und -1-hydrazonderivate, deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
HU189765B (en) 1983-10-25 1986-07-28 Richter Gedeon Vegyeszeti Gyar Rt,Hu Process for preparing n-substituted 1-(bis (hydroxy-metiol)-methyl)-isoquinoline-derivatives
US4619878A (en) 1984-06-26 1986-10-28 Ricoh Co., Ltd. Tetrazonium salt compound, disazo compound, method for preparing the same, and photosensitive material containing said disazo compound for use in electrophotography
DE3569368D1 (en) 1984-11-30 1989-05-18 Fisons Plc Angiotensin converting enzyme inhibitors and their production and use as pharmaceuticals
US4833153A (en) 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
IL77496A (en) 1986-01-01 1989-02-28 Univ Ramot Anti-viral preparations comprising isatine 3-thiosemicarbazones
WO1987006132A1 (en) 1986-04-07 1987-10-22 The Upjohn Company Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions
US5023334A (en) 1986-10-03 1991-06-11 The Upjohn Company Anthelmintic pyridinyl acylhydrazones
ATE111885T1 (de) 1987-09-09 1994-10-15 Zeneca Ltd Schimmelbekämpfungsmittel.
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US4958010A (en) 1988-02-16 1990-09-18 Bristol-Myers Company Epipodophyllotoxin glucoside lactam derivatives
ZA894508B (en) 1988-06-16 1990-03-28 Rohm & Haas Pharmaceutical compounds
JP2521137B2 (ja) 1988-11-08 1996-07-31 富士写真フイルム株式会社 電子写真感光体
US5196291A (en) 1989-05-24 1993-03-23 Fuji Photo Film Co., Ltd. Silver halide photographic material
EP0420005B1 (en) 1989-09-18 1996-07-10 Fuji Photo Film Co., Ltd. High contrast silver halide photographic material
US5135928A (en) 1989-10-25 1992-08-04 Egis Gyogyszergyar Triazolo derivatives and process for their preparation
US4985433A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US4985434A (en) 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US5008265A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5008270A (en) 1989-10-31 1991-04-16 Biocryst, Inc. 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
JP3093767B2 (ja) 1989-11-27 2000-10-03 松下電工株式会社 洗浄装置
US5189039A (en) 1989-11-29 1993-02-23 Biocryst, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
US5230983A (en) 1990-04-13 1993-07-27 Fuji Photo Film Co., Ltd. Silver halide photographic material
LU87766A1 (fr) 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JPH05333467A (ja) 1991-05-02 1993-12-17 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5344836A (en) 1991-11-11 1994-09-06 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
JP2787630B2 (ja) 1992-02-06 1998-08-20 富士写真フイルム株式会社 ハロゲン化銀感光材料
DE4207400A1 (de) 1992-03-09 1993-09-16 Bayer Ag Hydrazone
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5358946A (en) 1992-05-29 1994-10-25 The Du Pont Merck Pharmaceutical Company Heterocycle-substituted amides, carbamates and ureas as agents for the treatment of atherosclerosis
JP2994182B2 (ja) 1992-07-23 1999-12-27 石原産業株式会社 アミド系化合物又はその塩、それらの製造方法及びそれらを含有する有害動物防除剤
EP0600832A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Diaminobenzoe- und Diaminophthalsäurederivate und ihre Verfahren als Proteinkinase-Inhibitoren
TW251302B (enExample) 1992-12-28 1995-07-11 Kao Corp
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
JP3350739B2 (ja) 1993-06-10 2002-11-25 コニカ株式会社 黒白ハロゲン化銀写真感光材料の現像処理方法
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
KR100225721B1 (ko) 1994-02-23 1999-10-15 디. 제이. 우드, 스피겔 알렌 제이 4-헤테로사이클릴-치환된 퀴나졸린 유도체, 이들의 제조 방법 및항암제로서의 용도
WO1995027693A1 (en) 1994-04-06 1995-10-19 Shionogi & Co., Ltd. α-SUBSTITUTED PHENYLACETIC ACID DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND AGRICULTURAL BACTERICIDE CONTAINING THE SAME
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
TW280906B (enExample) 1994-12-01 1996-07-11 Ibm
DE19501481A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
JPH08220666A (ja) 1995-02-15 1996-08-30 Konica Corp 黒白ハロゲン化銀写真感光材料及びその処理方法
DE69613367T2 (de) 1995-04-27 2002-04-18 Astrazeneca Ab, Soedertaelje Chinazolin derivate
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
JPH11507052A (ja) 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
US5633786A (en) 1995-08-21 1997-05-27 Motorola Shield assembly and method of shielding suitable for use in a communication device
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE19545878A1 (de) 1995-12-08 1997-06-12 Basf Ag Pyridylcarbamate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
DE19619518A1 (de) 1996-05-15 1997-11-20 Haeussler & Sauter Kg Verfahren zur Anbringung eines Fadens an einem Aufgußbeutel
US6306574B1 (en) 1996-05-17 2001-10-23 Fuji Photo Film Co., Ltd. Photothermographic material
US20040171032A1 (en) 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2260058A1 (en) 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP0902028A1 (en) 1997-09-11 1999-03-17 E.I. Du Pont De Nemours And Company Tetrazoline herbicides
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6184377B1 (en) 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
CA2319836C (en) 1998-02-06 2010-11-23 De Montfort University Hydroxylation activated prodrugs
CA2330458A1 (en) 1998-04-29 1999-11-04 Georgetown University Methods of identifying and using hla binding compounds as hla-agonists and antagonists
US20010051628A1 (en) 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
US6289352B1 (en) 1998-05-29 2001-09-11 Crystal Decisions, Inc. Apparatus and method for compound on-line analytical processing in databases
JPH11345811A (ja) 1998-06-01 1999-12-14 Seiko Instruments Inc 半導体装置の製造方法
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20030181495A1 (en) 1998-06-23 2003-09-25 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
WO2000012084A1 (en) 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
JP2000143636A (ja) 1998-09-02 2000-05-26 Sumitomo Pharmaceut Co Ltd アミノ誘導体
US20020010550A1 (en) 1998-09-14 2002-01-24 George M. Grass Pharmacokinetic-based drug design tool and method
US6420560B1 (en) 1999-06-07 2002-07-16 Theravance, Inc. H1—histamine receptor antagonists
AU5469400A (en) 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2001019825A1 (en) 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
US7264932B2 (en) 1999-09-24 2007-09-04 Applera Corporation Nuclease inhibitor cocktail
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
JP2001172217A (ja) 1999-12-21 2001-06-26 Shionogi & Co Ltd 殺ダニ活性および殺菌活性を有するエチレン誘導体
GB2357971A (en) 1999-12-23 2001-07-11 Novartis Ag Protection of plants against microorganism attack
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
IL145757A (en) 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004500388A (ja) 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
GB2372562A (en) 2000-04-26 2002-08-28 Ribotargets Ltd In silico screening
EP1152010B1 (en) 2000-05-05 2010-04-21 Wallac Oy Oligonucleotide labeling reactants and their use
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6489094B2 (en) 2000-05-31 2002-12-03 Pfizer Inc. Method and device for drug-drug interaction testing sample preparation
US7211192B2 (en) 2000-06-02 2007-05-01 The Regents Of The University Of California Hybrid organic-inorganic adsorbents
US7022484B2 (en) 2000-06-08 2006-04-04 Board Of Regents, The University Of Texas System Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
BR0112355A (pt) 2000-06-26 2005-04-19 Univ Michigan Uso de inibidores da proteìna egf-r tirosina cinase para a prevenção do fotoenvelhecimento da pele humana
AU2001276934A1 (en) 2000-07-18 2002-02-05 Joslin Diabetes Center Inc. Methods of modulating fibrosis
US7067046B2 (en) 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
US6647342B2 (en) 2000-08-07 2003-11-11 Novodynamics, Inc. Knowledge-based process for the development of materials
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
WO2002094019A1 (en) 2001-05-22 2002-11-28 Eisai Co., Ltd Highly purified antiendotoxin compound
JP2002361158A (ja) 2001-06-07 2002-12-17 Aica Kogyo Co Ltd 塗布装置
US6352168B1 (en) 2001-06-21 2002-03-05 Jung-Chuang Lin Rotation cup
WO2003004489A1 (en) 2001-07-05 2003-01-16 Gpc Biotech Inc. Compositions and methods for inhibiting prenyltransferases
JP2004534097A (ja) 2001-07-09 2004-11-11 フアルマシア・イタリア・エツセ・ピー・アー ＴＣＦ−４とβ−カテニンの相互作用阻害剤
AU2003216322A1 (en) 2002-02-15 2003-09-09 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US7202367B2 (en) 2002-05-31 2007-04-10 Rhodia Chimie Process for arylating or vinylating or alkynating a nucleophilic compound
CA2502478A1 (en) 2002-10-18 2004-05-06 Basf Aktiengesellschaft 1-phenylpyrrolidine-2-one-3-carboxamides
CA2515027A1 (en) 2003-02-05 2004-08-19 Unisearch Limited Metal ion chelators and therapeutic use thereof
CA2515515A1 (en) 2003-02-18 2004-09-02 Whitehead Institute For Biomedical Research Mtor kinase-associated proteins
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
US20040193538A1 (en) 2003-03-31 2004-09-30 Raines Walter L. Receipt processing system and method
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US20050010017A1 (en) 2003-07-11 2005-01-13 Blakely Dale Milton Addition of UV inhibitors to pet process for maximum yield
WO2005039489A2 (en) 2003-09-24 2005-05-06 Polymerix Corporation Compositions and methods for the inhibition of bone growth and resorption
CN1909906A (zh) * 2004-01-20 2007-02-07 默克公司 作为趋化因子受体活性调节剂的2,6－二取代的哌啶类化合物
UA84050C2 (en) 2004-01-30 2008-09-10 Медивир Аб Hcv ns-3-serine protease inhibitors
WO2005087211A1 (en) 2004-03-05 2005-09-22 The Regents Of The University Of California Anti-parasitic compounds and methods of their use
WO2006040039A1 (de) * 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
FR2879194B1 (fr) 2004-12-14 2007-01-19 Galderma Res & Dev Nouveaux composes bi-aromatiques modulateurs des recepteurs de type ppar, leur procede de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
JP2006181940A (ja) 2004-12-28 2006-07-13 Mitsubishi Paper Mills Ltd インクジェット用記録材料
CN1891701A (zh) 2005-07-07 2007-01-10 桑迪亚医药技术（上海）有限责任公司 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用
CN100497309C (zh) 2005-08-04 2009-06-10 卡南吉医药科技（上海）有限公司 杂芳环缩氨基硫脲类抗肿瘤药物的合成方法
CA2620878A1 (en) 2005-08-29 2007-04-05 Gerard M. Housey Theramutein modulators
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
JP2008008853A (ja) 2006-06-30 2008-01-17 Univ Of Electro-Communications 地点間距離変動検出装置及び方法
JP2008088107A (ja) 2006-10-02 2008-04-17 Fujiyakuhin Co Ltd 新規ピリダジン誘導体
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer

Also Published As

Publication number Publication date
CA2673683A1 (en) 2008-07-17
US20080171744A1 (en) 2008-07-17
JP5571387B2 (ja) 2014-08-13
US20120077820A1 (en) 2012-03-29
EP2121681A1 (en) 2009-11-25
JP2010515693A (ja) 2010-05-13
WO2008083491A1 (en) 2008-07-17
US8420643B2 (en) 2013-04-16
US20110281887A1 (en) 2011-11-17
US8822475B2 (en) 2014-09-02
EP2121681A4 (en) 2011-06-15
US8034815B2 (en) 2011-10-11
EP2121681B1 (en) 2015-04-15
US20130165449A1 (en) 2013-06-27
US8367675B2 (en) 2013-02-05
CA2673683C (en) 2014-07-29

Similar Documents

Publication Publication Date Title
IL229878A (en) Cancer Treatment Compounds
IL197315A0 (en) Treatment of cancer
ZA201006988B (en) Method and compositions for treatment of cancer
IL199689A0 (en) Compounds and method for treatment of cancer
EP2144504A4 (en) METHOD FOR COMBATING BRAIN CANCER
SI2054066T1 (sl) Postopki za zdravljenje radiacijskega enteritisa
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
IL238394A0 (en) Cancer treatment method
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
ZA201101216B (en) Organoarsenic compounds and methods for the treatment of cancer
EP2198041A4 (en) METHOD AND COMPOSITION FOR CANCER DIAGNOSIS AND TREATMENT
IL226363A0 (en) Compounds and methods for treating cancer
IL196727A0 (en) Composition and method for treatment of tumors
IL205339A0 (en) Compounds and methods for the treatment of cancer
EP2203432A4 (en) PROCESSING METHOD
GB0600903D0 (en) Treatment of cancer
GB0717337D0 (en) Method of treatment
IL196361A0 (en) Combination methods of treating cancer
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0712513D0 (en) Treatment of cancer
GB0622581D0 (en) Treatment of cancer